FRX Innovations, Inc. is a medical technology company specializing in the development and commercialization of minimally invasive surgical solutions. The company’s core focus lies in radiofrequency and plasma-based ablation systems designed to safely coagulate, cut and remove soft tissue across a range of clinical applications. FRX Innovations combines proprietary energy-delivery platforms with single-use probe technology to address evolving needs in modern surgery.
Its flagship product line includes compact, user-friendly generators paired with dedicated electrode and catheter configurations for endoscopic, laparoscopic and open procedures. These offerings cater to specialties such as otolaryngology, gynecology, general surgery and interventional cardiology, enabling precise tissue treatment while minimizing collateral damage. The company continuously refines its disposable accessory portfolio to streamline setup and reduce operative time.
FRX Innovations markets its devices through a hybrid distribution model, leveraging both direct sales teams and international partners. Its systems carry regulatory clearances in the United States, European Union and select Asia Pacific markets, with a growing installed base in hospitals and ambulatory surgical centers. The company also collaborates with leading academic institutions and clinical research organizations to validate new indications and expand its technology footprint.
Founded in 2018 and headquartered in Minneapolis, Minnesota, FRX Innovations was established by a multidisciplinary team of engineers and physicians. The executive leadership brings extensive backgrounds in medical device research, regulatory affairs and commercial strategy. Looking ahead, the company is investing in next-generation ablation platforms and strategic alliances to drive long-term growth and deliver advanced procedural solutions to surgeons worldwide.
AI Generated. May Contain Errors.
